$CCCC News
Last published 2d ago
- 2d agoCCCCC4 Therapeutics, Inc. (CCCC) - Guggenheim 3rd Annual Healthcare Innovation Conference - C4 THERAPEUTICS INCEarnings Call TranscriptsAll right, so welcome to this next Five-Side Chat with C4 Therapeutics. My name is Michael Schmidt, and I'd like to welcome the management team here, starting with Andrew Hirsch, CEO. Andrew, for investors who are just g
- 2d agoCCCCGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - C4 THERAPEUTICS INCEarnings Call TranscriptsAll right, so welcome to this next Five-Side Chat with C4 Therapeutics. My name is Michael Schmidt, and I'd like to welcome the management team here, starting with Andrew Hirsch, CEO. Andrew, for investors who are just g
- 6d agoCCCCC4 Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoCCCCC4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireCemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab;
- 1w agoCCCCC4 Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswireWATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 1w agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1w agoCCCCC4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue DegradersGlobeNewswireWATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 3w agoINSMCCCCInsmed Appoints Two New Directors to Its BoardPR Newswire—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors—BRIDGEWATER, N.J., Oct. 20, 2026
- 2mo agoCCCCC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingGlobeNewswireWATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 3mo agoCCCCC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireCemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA)
- 3mo agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 4mo agoCCCCEducational KOL Webinar on the Evolving Multiple Myeloma Treatment Landscape, the Role of IKZF1/3 Degradation and Cemsidomide's Profile - C4 THERAPEUTICS INCEarnings Call TranscriptsGood day and welcome to the educational KOL webinar. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today'
- 5mo agoCCCCC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory PopulationGlobeNewswireAt the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With
- 5mo agoCCCCC4 Therapeutics to Participate in Upcoming ConferencesGlobeNewswireWATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 5mo agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that
- 6mo agoCCCCC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireProgressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b
- 7mo agoCCCCRHHBYC4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)GlobeNewswireAgreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to
- 7mo agoCCCCC4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple MyelomaGlobeNewswireWATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 8mo agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 8mo agoONCYVIRIOVACCCC+1Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesPR NewswireEquity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress ...
- 8mo agoCCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswireCemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of
- 8mo agoCCCCC4 Therapeutics to Participate in Upcoming March ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 8mo agoCCCCC4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple MyelomaGlobeNewswireEnrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE
- 9mo agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 9mo agoCCCCC4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireWATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today
- 9mo agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 10mo agoCCCCC4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysGlobeNewswireCemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery
- 11mo agoCCCCC4 Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireCompleted Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase
- 1y agoGTBPNRIXGRALCCCC+1Precision Oncology Approaches Drive $312B Market TransformationPR NewswireUSA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting...
- 1y agoCCCCC4 Therapeutics Announces Pricing of $125 Million Underwritten OfferingGlobeNewswire$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with
- 1y agoCCCCC4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewswireWATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual MeetingGlobeNewswireCemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple
- 1y agoONCYHCMCGONCCCC+1Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape MarketPR NewswireUSA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
- 1y agoCCCCC4 Therapeutics Highlights Recent Achievement in Biogen CollaborationGlobeNewswireWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual MeetingGlobeNewswireWATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireCemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose
- 1y agoCCCCC4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireUpdated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One
- 1y agoCCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswirePlanning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress
- 1y agoCCCCC4 Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in OncologyGlobeNewswireCemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma
- 1y agoCCCCC4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 1y agoCCCCC4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderGlobeNewswireIn Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across
- 1y agoCCCCC4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsGlobeNewswireHoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN,
- 2y agoCCCCC4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialGlobeNewswireWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its
- 2y agoCCCCC4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual MeetingGlobeNewswireWATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
- 2y agoABBVCCCCIMGNNVS+1PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial OfficerBusiness WireFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a
- 2y agoABBVCCCCIMGNNVSSeaport Therapeutics Names Lauren White as Chief Financial OfficerBusiness WireFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that
- 2y agoCCCCC4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireCemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego,
- 2y agoCCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced